A bellwether stock in the lately rather up-and-down pharmaceutical sector, AbbVie (NYSE: ABBV) finished the trading week in style. The company’s shares closed more than 3% higher in price thanks in no small part to a clutch of post-earnings analyst price-target increases. With that performance, Abbvie crushed the S&P 500 index, which dived by 1.6% on the day.
As typically happens when a publicly traded company posts better-than-expected quarterly results, those pundits made the positive changes a day after AbbVie published its estimates-besting second-quarter figures.
Image source: Getty Images.